MBX Biosciences, Inc. (NYSE:MBX) CEO P. Kent Hawryluk Buys 50,000 Shares

MBX Biosciences, Inc. (NYSE:MBX) CEO P. Kent Hawryluk purchased 50,000 shares of MBX Biosciences stock in a transaction dated Tuesday, February 4th. The stock was bought at an average price of $10.69 per share, for a total transaction of $534,500.00. Following the completion of the purchase, the chief executive officer now owns 448,277 shares in the company, valued at $4,792,081.13. This represents a 12.55 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

MBX Biosciences Stock Up 2.9 %

Shares of NYSE:MBX opened at $11.25 on Thursday. MBX Biosciences, Inc. has a one year low of $9.42 and a one year high of $27.50. The company has a 50 day moving average of $16.47.

MBX Biosciences (NYSE:MBX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($2.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.72) by ($0.06). On average, research analysts forecast that MBX Biosciences, Inc. will post -13.21 earnings per share for the current fiscal year.

Institutional Trading of MBX Biosciences

A number of hedge funds have recently made changes to their positions in MBX. Rhumbline Advisers acquired a new stake in MBX Biosciences during the 4th quarter worth approximately $175,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of MBX Biosciences during the third quarter valued at $278,000. Point72 Asset Management L.P. bought a new stake in shares of MBX Biosciences in the third quarter worth $405,000. Barclays PLC bought a new stake in shares of MBX Biosciences in the third quarter worth $426,000. Finally, Bank of New York Mellon Corp acquired a new stake in MBX Biosciences in the fourth quarter valued at $441,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.